1. Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant
- Author
-
Mlcochova, Petra, Collier, Dami, Ritchie, Allyson, Assennato, Sonny M, Hosmillo, Myra, Goel, Neha, Meng, Bo, Chatterjee, Krishna, Mendoza, Vivien, Temperton, Nigel, Kiss, Leo, James, Leo C, Ciazynska, Katarzyna A, Xiong, Xiaoli, Briggs, John AG, Nathan, James A, Mescia, Federica, Bergamaschi, Laura, Zhang, Hongyi, Barmpounakis, Petros, Demeris, Nikos, Skells, Richard, Lyons, Paul A, Bradley, John, Baker, Steven, Allain, Jean Pierre, Smith, Kenneth GC, Bousfield, Rachel, Wilson, Michael, Sparkes, Dominic, Amoroso, Glenn, Gkrania-Klotsas, Effrosyni, Hardwick, Susie, Boyle, Adrian, Goodfellow, Ian, Gupta, Ravindra K, Cambridge Institute Of Therapeutic Immunology And Infectious Disease-National Institute Of Health Research (CITIID-NIHR) COVID BioResource Collaboration, Mlcochova, Petra [0000-0001-6908-9363], Hosmillo, Myra [0000-0002-3514-7681], Chatterjee, Krishna [0000-0002-2654-8854], Kiss, Leo [0000-0001-8735-1118], Nathan, James [0000-0002-0248-1632], Mescia, Federica [0000-0002-2759-4027], Lyons, Paul [0000-0001-7035-8997], Bradley, John [0000-0002-7774-8805], Baker, Stephen [0000-0003-1308-5755], Gkrania-Klotsas, Effrossyni [0000-0002-0930-8330], Gupta, Ravindra [0000-0001-9751-1808], and Apollo - University of Cambridge Repository
- Subjects
Aged, 80 and over ,Immunoassay ,Male ,point of care testing ,SARS-CoV-2 ,COVID-19 ,Middle Aged ,D614G ,Antibodies, Viral ,Sensitivity and Specificity ,COVID-19 Testing ,rapid diagnoses ,Neutralization Tests ,Point-of-Care Testing ,Spike Glycoprotein, Coronavirus ,Humans ,Female ,Nucleic Acid Amplification Techniques ,Aged - Abstract
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8-92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.
- Published
- 2020